We profiled the genome, transcriptome, proteome and phosphoproteome of 145 cases of localized prostate cancer (PCa) in Chinese patients and revealed three subtypes with distinct molecular features. We integrated multi-omic data to refine molecular subtyping of localized PCa, and identified NANS as a potential prognostic biomarker and therapeutic option for aggressive PCa.